6Matsumoto K,Takeshita A,Ikawa K,et al. Higher linezolid expo- sure and higher frequency of thromhocytopenia in patients with renaldysfunction[J]. Int J Antimicrob Agents, 2010,36 (2) : 179 - 181.
7Liu XD,Jian LY,Wan GF. Literature of linezolid adverse reactions [J]. Her Med,2012,31(6):811 -813.
5Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom [ J ]. J Antimierob Chemother, 2000,45 ( 2 ) : 225 - 230.
6Jones RN, Fritsche TR,Sader HS, et al. Zyvox annual appraisal of potency and spectrum program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries [ J ]. Diagn Microbiol Infect Dis,2007,59 (2) : 199 - 209.
7Wang H,Liu Y, Sun H,et al. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China[ J ]. Diagn Microbiol Infect Dis, 2008,62 (2) :226 - 229.
8Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period [ J ]. J Clin Microbiol, 2006,44 ( 11 ) : 3883 - 3886.
9Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group Ⅱ polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy[ J]. Clin Infect Dis,2004 ,38 (12) : 1700 - 1705.
10Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharrnacodynamic aspects of linezolid with infection outcome[J]. Curr Drug Metab,2009,10( 1 ) :2 - 12.
